Role of TNF inhibitors in AS and Role of JAK inhibitors in RA.

Speciality: Rheumatology

Description:

A warm welcome to all the medical professionals in this interesting session on Role of TNF inhibitors in AS and Role of JAK inhibitors in RA.
Tumor necrosis factor (TNF) inhibitors have revolutionized the treatment of ankylosing spondylitis (AS), a chronic inflammatory disease primarily affecting the spine and sacroiliac joints. TNF inhibitors, such as infliximab, etanercept, and adalimumab, target and neutralize TNF-α, a cytokine that plays a key role in the inflammatory processes of AS. By reducing inflammation, these biologic agents help alleviate symptoms such as pain, stiffness, and swelling, significantly improving patients' quality of life. Clinical trials and real-world studies have shown that TNF inhibitors can also slow the progression of spinal damage, preserving mobility and function in patients with AS. Their favorable safety and efficacy profiles make TNF inhibitors a cornerstone in the management of moderate to severe AS.
Janus kinase (JAK) inhibitors represent a newer class of targeted synthetic disease-modifying antirheumatic drugs (DMARDs) for the treatment of rheumatoid arthritis (RA). JAK inhibitors, such as tofacitinib, baricitinib, and upadacitinib, work by blocking the activity of JAK enzymes, which are involved in the signaling pathways that drive inflammation and autoimmune responses in RA. By inhibiting these pathways, JAK inhibitors help reduce inflammation, decrease joint pain and swelling, and prevent joint damage.
Therefore, get an overall knowledge of updated role of TNF inhibitors in AS and role of JAK inhibi

See More Webinars @ Hidoc Webinars